Premium
The long‐term outcome of patients with polycystic liver disease treated with lanreotide
Author(s) -
Chrispijn M.,
Nevens F.,
Gevers T. J. G.,
Vanslembrouck R.,
van Oijen M. G. H.,
Coudyzer W.,
Hoffmann A. L.,
Dekker H. M.,
de Man R. A.,
van Keimpema L.,
Drenth J. P. H.
Publication year - 2012
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2011.04923.x
Subject(s) - lanreotide , medicine , polycystic liver disease , gastroenterology , placebo , urology , clinical endpoint , liver disease , somatostatin , polycystic disease , surgery , endocrinology , clinical trial , pathology , hormone , kidney , liver transplantation , growth hormone , transplantation , alternative medicine , acromegaly
Aliment Pharmacol Ther 2012; 35: 266–274 Summary Background Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume. Aim To establish long‐term outcome and safety of lanreotide. Methods This was an open‐label, observational extension study of a 6‐month, randomised, placebo‐controlled trial with lanreotide (120 mg/month) in PLD. The length of total treatment was 12 months. Primary endpoint was relative change in liver volume, as determined by CT‐volumetry after 12 months of treatment. We offered patients a CT scan 6 months after stopping lanreotide. Results A total of 41/54 (76%) patients participated in the extension study. Liver volume decreased by 4% (IQR −8% to −1%) after 12 months of treatment. The greatest effect was observed during the first 6 months of treatment (decrease of 4% (IQR −6% to −1%)). Liver volume remained unchanged during the following 6 months. We found that liver volume increased by 4% (IQR 0–6%) 6 months after end of treatment ( n = 22). Conclusions Lanreotide reduces liver volume within the first 6 months of treatment and the beneficial effect is maintained in the following 6 months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect.